Major Depressive Disorder: The Importance of Patient-Centered Outcomes

Bradley Neil Gaynes, MD, MPH

Disclosures

October 03, 2022

Bradley Neil Gaynes, MD, MPH, in summarizing the changes that have occurred in therapy for major depressive disorder (MDD) over the past several decades, reviews the more recent pharmacologic drugs added to the psychiatric treatment inventory, including nonstandard agents like ketamine, and also touches on other modes, specifically transcranial magnetic stimulation.

This accumulation of therapies, Dr Gaynes suggests, in turn feeds a constantly widening circumference of awareness regarding patient response, so that assessment of progress is based not just in the application of individual clinical points but also in the greater context of patients' lives, which includes more nuanced and far-reaching measures of success.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....